The companies will join forces to advance the use of precision medicine globally
BOSTON and ROLLS, Switzerland, April 4, 2024 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-based healthcare software company and leader in data-driven medicine, today announced a strategic partnership with Strand Life Sciences, a pioneer in bioinformatics and diagnostics, to deliver innovative solutions that will encourage the use of precision medicine on a global scale. The new collaboration will leverage the leadership strengths of both companies to provide access to advanced genomic technologies, cutting-edge bioinformatics services and innovative diagnostic solutions.
Headquarters in Bangalore, India, Strand is a life sciences technology company with expertise in bioinformatics, laboratory testing, clinical research and software development. It supports a broad global user base with its customized applications that help expand and improve the use of precision medicine around the world.
“We are excited about our collaboration with SOPHiA GENETICS that will seek to leverage our combined expertise in bioinformatics to help partner organizations around the world deliver next-generation precision medicine to improve patient care,” he said. Ramesh HariharanCEO and co-founder of Strand.
Through the broad collaboration between SOPHiA GENETICS and Strand, the two companies will leverage their bioinformatics expertise to expand the ability to precisely analyze key health data and facilitate the global use of data-driven decision-making. SOPHiA GENETICS will provide support through the decentralized SOPHiA DDM™ platform and Strand through its selected variant databases and bioinformatics solutions expertise, and the companies will collaborate to jointly develop strategic assays, among other initiatives, that will seek to improve health outcomes in India and globally.
“Strand and SOPHiA GENETICS share a vision of improving patient health outcomes through precision medicine,” said Dr. Jurgi Camblong, CEO and co-founder of SOPHiA GENETICS. “It is imperative that healthcare organizations have the ability to process previously hidden data in a timely manner and obtain highly accurate results that facilitate rapid and effective treatment of cancer and rare diseases. This strategic partnership will further enable innovation.”
The SOPHiA DDM™ Platform is designed to compute a wide range of genomic variants and continuously refine machine learning algorithms. With their sophisticated technologies and bioinformatics expertise, SOPHiA GENETICS and Strand will jointly deepen their value propositions.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM or connect to xLinkedIn, Facebook and Instagram.
ON SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care for life science research. He is the creator of the SOPHiA DDM™ platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ platform and related solutions, products and services are currently used by a wide network of hospitals, laboratories and biopharmaceutical facilities worldwide. For more information visit SOPHiAGENETICS.COM or connect to xLinkedIn, Facebook and Instagram. Where others see data, we see answers.
About Strand Life Sciences
Strand Life Sciences Private Limited is a genomics-based research and diagnostics company that combines a long experience in bioinformatics with state-of-the-art laboratory tests and a wide network of hospital partners for encourage new generations of patient care. Strand’s customers include global instruments, diagnostics and pharmaceutical companies. Strand is also a pioneer in genomic testing in the India. Strand has long been global bioinformatics results make it the most trusted company for genomic diagnostics in the fields oncology, rare diseases, women’s health and infectious diseases.
SOPHiA GENETICS products are for research use only and not for use in diagnostic procedures unless otherwise specified. The information in this press release relates to products that may or may not be available in different countries and, if applicable, may or may not have received approval or market approval from a country’s regulatory authority for different indications of use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS’ forward-looking statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical fact contained in this press release, including statements about our future results of operations and financial position, business strategy, products and technology, and management’s plans and objectives for future operations, are forward-looking statements. Forward-looking statements are based on the beliefs and assumptions of our management and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the US Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in the events, conditions or circumstances on which these statements are based, unless not required by applicable law. No representations or warranties (express or implied) are made as to the accuracy of any such forward-looking statement.
Logo – https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg
